VanEck Associates’s Adaptive Biotechnologies ADPT Stock Holding History

VanEck Associates’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,787	Closed	-$10K	–	1392
2023 Q3	$10K	Hold	1,787	–	–	﹤0.01%	1354
2023 Q2	$12K	Hold	1,787	–	–	﹤0.01%	1359
2023 Q1	$16K	Sell	1,787 -6	-0.3%	-$53	﹤0.01%	1359
2022 Q4	$14K	Buy	1,793 +309	+21%	+$2.4K	﹤0.01%	1370
2022 Q3	$11K	Buy	+1,484	New	+$14K	﹤0.01%	1336

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

VanEck Associates's ADPT Position: Q4 2023 in Review

VanEck Associates sold out of Adaptive Biotechnologies (ADPT) in Q4 2023, closing a stake of 1,787 shares — an estimated $10K sold.

VanEck Associates first reported a position in ADPT in Q3 2022 and held it in 5 quarters. The position peaked at $16K in Q1 2023. 200 funds tracked by Wall St. Rank hold ADPT as of Q4 2023.

VanEck Associates reported no remaining Adaptive Biotechnologies position as of Q4 2023 after selling out during the quarter.
VanEck Associates sold 1,787 Adaptive Biotechnologies shares in Q4 2023, an estimated $10K.
VanEck Associates first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 5 quarters.
VanEck Associates's Adaptive Biotechnologies position peaked at $16K in Q1 2023.
200 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2023.

Based on VanEck Associates's 13F filing for Q4 2023, filed 5 Feb 2024.